Clinical Trials
Multiple clinical trials investigate the therapeutic utility of flecainide across cardiac conditions, including atrial fibrillation, paroxysmal atrial fibrillation, general cardiac arrhythmias, and arrhythmogenic right ventricular cardiomyopathy. Encompassing Phase 2, Phase 4, and unassigned phases, these studies are sponsored by academic medical centers, university hospitals, and cardiovascular research societies such as the University of Rochester and the Hellenic Cardiovascular Research Society. Most recorded trials have a completed recruitment status, alongside a clinical trial with an unknown status.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04991896 | Completed | Atrial Fibrillation|Arrhythmias Cardiac |
AHEPA University Hospital|Skylitseio General Hospital |
2020-01-01 | -- |
| NCT03685149 | Completed | Arrhythmogenic Right Ventricular Cardiomyopathy |
Wojciech Zareba|University of Rochester |
2019-07-31 | Phase 2 |
| NCT03005366 | Completed | Paroxysmal Atrial Fibrillation |
David Filgueiras-Rama|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|Hospital San Carlos Madrid |
2017-01 | Phase 4 |
| NCT02190175 | Completed | Atrial Fibrillation |
Hellenic Cardiovascular Research Society |
2014-06 | -- |
| NCT00945867 | Unknown status | Atrial Fibrillation |
Assaf-Harofeh Medical Center |
2009-09 | -- |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).